Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease in the Western countries, affecting up to 25% of the general population and becoming a major health concern in both adults and children. NAFLD encompasses the entire spectrum of fatty liver disease in individuals without significant alcohol consumption, ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) and cirrhosis. NASH is a manifestation of the metabolic syndrome and hepatic disorders with the presence of steatosis, hepatocyte injury (ballooning), inflammation, and, in some patients, progressive fibrosis leading to cirrhosis. The pathogenesis of NASH is a complex process and implicates cell interactions between liver parenchymal and nonparenchymal cells as well as crosstalk between various immune cell populations in liver. Lipotoxicity appears to be the central driver of hepatic cellular injury via oxidative stress and endoplasmic reticulum (ER) stress. This review focuses on the contributions of hepatocytes and nonparenchymal cells to NASH, assessing their potential applications to the development of novel therapeutic agents. Currently, there are limited pharmacological treatments for NASH; therefore, an increased understanding of NASH pathogenesis is pertinent to improve disease interventions in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“M2-polarized macrophages counterbalance M1 macrophage-induced inflammation, promoting resolution of inflammation and tissue repair [63].”
BackgroundBataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation
Italiani, P., & Boraschi, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00514 · Cited by 2,067
Cited by
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Arroyave-Ospina, J. C., Wu, Z., Geng, Y., & Moshage, H. (2021) · Antioxidants · doi:10.3390/antiox10020174 · Cited by 527
Choi, H. S. J., Brouwer, W. P., Zanjir, W. M. R., de Man, R. A., Feld, J. J., Hansen, B. E., Janssen, H. L. A., & Patel, K. (2020) · Hepatology · doi:10.1002/hep.30857 · Cited by 211
“(30) In patients with NAFLD progression, excessive free fatty acid accumulation within hepatocytes leads to mitochondrial and peroxisomal dysfunction, leading to enhanced oxidative stress, production of toxic lipid metabolites, and ongoing hepatocyte injury through activation of nuclear factor kappa B and proinflammat…”
BackgroundBeheshti, A., Chakravarty, K., Fogle, H., Fazelinia, H., Silveira, W. A. D., Boyko, V., Polo, S.-H. L., Saravia-Butler, A. M., Hardiman, G., Taylor, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55869-2 · Cited by 90
Kostrzewski, T., Snow, S., Battle, A. L., Peel, S., Ahmad, Z., Basak, J., Surakala, M., Bornot, A., Lindgren, J., Ryaboshapkina, M., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02616-x · Cited by 52
Aghadi, M., Elgendy, R., & Abdelalim, E. M. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05158-0 · Cited by 36
“The presence of ER stress, lipid accumulation, and hepatic cholestasis leads to hepatocellular injury activation and hepatic steatosis, enhancing the release of profibrogenic factors and stimulating the activation and propagation of HSCs, mainly through activation of the PI3K pathway [34, 35].”
BackgroundA Model of Hepatic Steatosis with Declined Viability and Function in a Liver-Organ-on-a-Chip
Wiriyakulsit, N., Keawsomnuk, P., Thongin, S., Ketsawatsomkron, P., & Muta, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-44198-0 · Cited by 29
“…model of steatosis with a hepatic cell line might be sufficient to replicate some of the biological features of the liver, the pathology of NAFLD, and the drug responses found in humans, but with some limitations such as inflammatory responses generally mediated by the non-parenchymal cells 44 .”
Metadata
- Authors
- Magee, N., Zou, A., & Zhang, Y.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-11
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2529961457
- Cited by
- 107
- References
- 44
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.